Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Philogen S.p.A. (PHIL.MI)
Sovicille, SI, IT
Philogen S.p.A. is a biotechnology firm dedicated to creating therapeutic agents for cancer and persistent inflammatory conditions. Among its pipeline, Nidlegy is being developed as an intralesional therapy for localized melanoma and non-melanoma skin cancers, combining the immunocytokines L19IL2 and L19TNF. Another key product is Fibromun, a human immunomodulatory agent composed of the L19 antibody and TNF, aimed at treating soft tissue sarcoma, leiomyosarcoma, and glioma. Darleukin, also known as L19IL2, is a human immunostimulatory product that integrates the human L19 antibody with the human cytokine interleukin-2 (IL2); it is currently undergoing Phase II clinical trials for addressing non-small cell lung cancer. The company's developmental efforts also include Dodekin, a human immunostimulatory product in Phase I/II clinical trials, consisting of a vascular targeting antibody fused with interleukin-12, designed to combat advanced solid tumors. For chronic inflammation, Dekavil (F8IL10), an anti-inflammatory compound, is in Phase I clinical trials. Furthermore, Philogen is advancing diagnostic radiotracers: Onco IX (PHC-102), a 99mTc labelled small molecule, is in Phase I, intended for the non-invasive detection of solid tumors that express carbonic anhydrase IX (CAIX). Similarly, OncoFAP, another small molecule radiotracer, is also in Phase I, focusing on the non-invasive identification of various metastatic solid tumors by targeting fibroblast activation protein. Established in 1996, Philogen S.p.A. operates from its headquarters in Sovicille, Italy.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.15% | +1.62% | +10.27% | +1.39% | -6.01% | -5.60% | -2.67% | +41.29% | +41.29% | +41.29% | +41.29% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+324.8% ★ Q4'25: +308.7% (vs Q4'24)
-
EPS growth Biotechnology: +29.7%+408.9% ★ Q4'25: +302.7% (vs Q4'24)
-
FCF margin FCF growth · Biotechnology: +16.2%+69.8% ★ Q4'25: +89.2% (vs Q4'24)
-
EBIT margin Biotechnology: +0.0%+80.0% ★ Q4'25: +87.7% (vs Q4'24)
-
ROIC Biotechnology: -16.1%+4,017.9% ★ Q4'25: +8,767.5% (vs Q4'24)
-
Share dilution Biotechnology: -3.4%0.0% ★ Q4'25: +0.5% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.04× ★ Q4'25: 0.02× (vs Q4'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.50M
est: 6.50M (-61.6%)
|
23.71M
est: 31.17M (-23.9%)
|
23.13M
est: 3.92M (+490.2%)
|
74.00M
est: 140.47M (-47.3%)
|
314.33M
est: 349.50M (-10.1%)
|
54.83M
8.90M – 145.39M
-84.3% YoY
|
47.36M
11.49M – 71.18M
-13.6% YoY
|
66.72M
13.16M – 143.70M
+40.9% YoY
|
147.67M
29.12M – 318.02M
+121.3% YoY
|
439.70M
86.70M – 946.92M
+197.8% YoY
|
| EBITDA |
-12.98M
est: -1.99M (-551.2%)
|
-1.17M
est: -9.56M (+87.7%)
|
-2.05M
est: 220.1K (-1,030.2%)
|
44.75M
est: 7.89M (+467.3%)
|
255.84M
est: 19.63M (+1,203.6%)
|
3.08M
499.8K – 8.16M
-84.3% YoY
|
2.66M
645.3K – 4.00M
-13.6% YoY
|
3.75M
738.8K – 8.07M
+40.9% YoY
|
8.29M
1.64M – 17.86M
+121.3% YoY
|
24.69M
4.87M – 53.17M
+197.8% YoY
|
| EBIT |
-14.84M
est: -2.42M (-513.5%)
|
-3.95M
est: -11.60M (+65.9%)
|
-5.69M
est: -47.1K (-11,987.2%)
|
40.90M
est: -1.69M (+2,524.5%)
|
251.58M
est: -4.20M (+6,094.7%)
|
-658.3K
-1.75M – -106.9K
+84.3% YoY
|
-568.7K
-854.7K – -138.0K
+13.6% YoY
|
-801.2K
-1.73M – -158.0K
-40.9% YoY
|
-1.77M
-3.82M – -349.6K
-121.3% YoY
|
-5.28M
-11.37M – -1.04M
-197.8% YoY
|
| Net Income |
-15.73M
est: -20.35M (+22.7%)
|
-5.38M
est: -940.1K (-471.9%)
|
-6.16M
est: -29.35M (+79.0%)
|
45.29M
est: 45.91M (-1.4%)
|
229.68M
est: 229.68M (+0.0%)
|
-46.64M
-48.43M – 58.10M
-120.3% YoY
|
-20.03M
-22.47M – -6.29M
+57.0% YoY
|
-6.76M
-13.75M – 240.3K
+66.3% YoY
|
-13.82M
-34.55M – 603.6K
-104.6% YoY
|
—
— – —
+100.0% YoY
|
| SGA |
-9.88M
est: -8.78M (-12.6%)
|
-12.07M
est: -42.08M (+71.3%)
|
-16.47M
est: -4.00M (-311.3%)
|
2.38M
est: -143.47M (+101.7%)
|
12.74M
est: -356.96M (+103.6%)
|
-56.00M
-148.49M – -9.09M
+84.3% YoY
|
-48.37M
-72.70M – -11.74M
+13.6% YoY
|
-68.15M
-146.76M – -13.44M
-40.9% YoY
|
-150.82M
-324.81M – -29.74M
-121.3% YoY
|
-449.09M
-967.14M – -88.55M
-197.8% YoY
|
| EPS |
-0.40
est: -0.51 (+20.8%)
|
-0.13
est: -0.02 (-457.2%)
|
-0.15
est: -0.73 (+79.5%)
|
1.12
est: 2.24 (-50.1%)
|
5.70
est: 6.31 (-9.7%)
|
-0.13
-1.20 – 1.44
-102.0% YoY
|
-0.30
-0.56 – -0.16
-135.4% YoY
|
-0.14
-0.34 – 0.01
+54.4% YoY
|
-0.34
-0.86 – 0.01
-151.2% YoY
|
—
— – —
+100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Alfredo Covelli | Chief Medical Officer | — | — |
| Carolina Pepi | Head of Human Resources | — | female |
| Dario Neri | Co-Founder, Chief Executive Officer , MD, CSO, President of the Scientific Advisory Board & Director | — | — |
| Duccio Neri | Co-Founder & Executive Chairman | — | — |
| Emanuele Puca | Head of Investor Relations | — | — |
| Giovanni Neri | Co-Founder, MD, Head of IP & Licensing and Executive Director | — | — |
| Katia Lorizzo | Deputy CMO & Head of Clinical Operations | — | — |
| Laura Baldi | Chief Financial Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PHIL.MI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
